Guardant Health is a leading precision oncology company dedicated to helping patients at all stages of cancer live longer and healthier lives through the power of blood tests and the data they unlock. In July 2024, Guardant Shield™ became the first blood-based test approved by the U.S. Food and Drug Administration as a primary screening option for colorectal cancer (CRC) and meets the requirements for Medicare coverage. Most CRC related deaths occur in individuals who are not up to date with CRC screening highlighting that CRC screening is critical to reducing mortality from the disease. By incorporating screening into routine medical care, blood-based CRC screening has the potential to overcome many of the access barriers associated with current screening methods and increase screening adherence.